$1.04
3.70%
Nasdaq, Nov 13, 04:05 pm EST. Closed.
ISIN
US36269B1052
Symbol
GANX

Gain Therapeutics Inc Stock price

$1.04
-0.37 26.24% 1M
-0.74 41.57% 6M
-2.18 67.70% YTD
-1.95 65.22% 1Y
-1.75 62.72% 3Y
-7.52 87.85% 5Y
-9.96 90.55% 10Y
-9.96 90.55% 20Y
Nasdaq, Closing price Fri, Nov 13 2026
-0.04 3.70%
ISIN
US36269B1052
Symbol
GANX
Industry

Is Gain Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,087 stocks worldwide.

Key metrics

Basic
Market capitalization
$46.3m
Enterprise Value
$33.6m
Net debt
positive
Cash
$13.1m
Shares outstanding
43.3m
Valuation
P/E
negative
P/S | estimate
- | -
EV/Sales | estimate
- | -
EV/FCF | ex SBC
negative | negative
P/B
4.1
Financial Health
Equity Ratio
81.4%
Return on Equity
-
ROCE
-160.9%
ROIC
-2,269.4%
Debt/Equity
0.0
Share-Based Compensation & Dilution
SBC | % of Revenue
$1.8m | -
SBC as % of FCF
-
SBC Growth 1Y
10.2%
Share Count Growth 1Y
40.9%
Shareholder Yield
-40.9%
Financials
Revenue | estimate
$0.0 | $0.0
EBITDA
$-19.2m
EBIT
$-19.3m
Net Income
$-20.1m
Free Cash Flow | ex SBC
$-19.0m | $-20.8m
Growth
Revenue | estimate
- | -
EBITDA
-11.8%
EBIT
-11.8%
Net Income
-8.2%
Free Cash Flow
-2.7%
Margin
Gross
-
EBITDA
-
EBIT
-
Net
-
Free Cash Flow | ex SBC
- | -
More
EPS
$-0.5
FCF per Share
$-0.4
Short interest
8.9%
Employees
21
Rev per Employee
-

Gain Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

11 Analysts have issued a Gain Therapeutics Inc forecast:

10x Buy
91%
1x Hold
9%

Analyst Opinions

11 Analysts have issued a Gain Therapeutics Inc forecast:

Buy
91%
Hold
9%

Gain Therapeutics Inc Events

Upcoming Event
NOV
18
Q3 2026 Earnings Call
in 4 days
View Past Earnings Reaction

Financial data from Gain Therapeutics Inc

Jun '26
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 9.30 9.30
9% 9%
-
- Research and Development Expense 9.99 9.99
15% 15%
-
-19 -19
12% 12%
-
- Depreciation and Amortization 0.10 0.10
11% 11%
-
EBIT (Operating Income) EBIT -19 -19
12% 12%
-
Net Profit -20 -20
8% 8%
-

In millions USD.

Don't miss a Thing! We will send you all news about Gain Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Gain Therapeutics Inc Stock News

Neutral
GlobeNewsWire
●
4 days ago
BETHESDA, Md., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today reported financial results for the quarter ended September 30, 2026, and provided a corporate update.
Neutral
GlobeNewsWire
●
9 days ago
BETHESDA, Md., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced the presentation of two late-breaking posters at the 31st IAPRD World Congress on Parkinson's Disease and Related Disorders a...
Neutral
GlobeNewsWire
●
about one month ago
Milan, Italy, October 13, 2026 – Sibylla Biotech today announced key executive appointments, including Usman Azam, MD, as Chief Executive Officer and Gianluca Fuggetta, MSc, MBA, as Chief Financial Officer. Both bring significant international corporate expertise, with Dr. Azam contributing more than 25 years of global biopharmaceutical executive, scientific and clinical development leadership....
More Gain Therapeutics Inc News

Company Profile

Gain Therapeutics, Inc. is a redefining drug discovery company, which identifies and optimizes allosteric binding sites that never before targeted. Its See-Tx target identification platform uses the published 3D structure of enzymes and a proprietary computational technology to discover new allosteric binding sites and predict their druggability. The firm is also unlocking new treatment options to treat disorders characterized by protein misfolding. The company was founded by Khalid Islam in 2017 and is headquartered in Bethesda, MD.

Head office United States
CEO Mr. Mack
Employees 21
Founded 2017
Website www.gaintherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today